Big Pharma Just Bet $10 Billion On A Cancer Drug Startup. Here's Why.

Question: What do WhatsApp and a little-known (until recently) cancer research startup named Stemcentrx have in common? Answer: They're the top two largest private venture-backed acquisitions in history, after pharmaceutical giant AbbVie acquired the drug company earlier this month in a deal that values it at as high as $10 billion. (Facebook acquired WhatsApp in 2014 for $19 billion.) Not bad for a company that has yet to bring a product to market. What Stemcentrx (pronounced "stem-centrix") does have, however, is a unique -- and somewhat controversial -- approach to treating several forms of cancer. While most of today's treatments view cancer as a result of unchecked cell growth, wherein any cell is capable of becoming cancerous, Stemcentrx believes that cancer primarily sprouts from only one cell type: cancer stem cells. Cells in our bodies are constantly dying and being birthed anew. This process relies on stem cells, which are basically just cells that can grow into many other different types of cells. Over time, Stemcentrx's Chief Science Officer Dr. Scott Dylla told HuffPost, those stem cells -- like any other cell -- can accumulate genetic mutations. Given enough mutations, says Dylla, they may begin "to act abnormally and no longer play nice with their neighbors." In other words, they become cancerous. The stem cell theory of cancer posits that rogue stem cells are responsible for growing and perpetuating cancer, and that, unless the stem ce...
Source: Science - The Huffington Post - Category: Science Source Type: news

Related Links:

AbbVie is halting a study into a new treatment for glioblastoma.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
CONCLUSION: ELF3 showed selective expression in low-grade cell lines and tumor tissues. Overexpression of ELF3 in mesenchymal cell line UMUC3 resulted in reduced invasion and decreased expression of mesenchymal markers. We observe association of low ELF3 expression with increased risk and overall poor survival using publicly available data. ELF3-modulated reversal of EMT might be a useful strategy in the treatment of bladder cancer. PMID: 31104013 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
In this study, we aimed to explore the expressing pattern, clinical significance and potential function of a newly identified circRNA, hsa_circ_001569, in BC. RT-PCR was performed to detect the expression of hsa_circ_001569 in both BC tissues and cell lines. The associations between hsa_circ_001569 expression and clinicopathological features and prognosis in BC patients were statistically analyzed. Next, we investigated the effects of hsa_circ_001569 on the proliferation, apoptosis, migration and invasion in BC cells lines. The effects of abnormal hsa_circ_001569 expression on EMT pathway and PI3K/AKT pathway were determin...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
CONCLUSIONS: Our results proved that PANDAR may serve as potential target of breast cancer treatment. PMID: 31104011 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
CONCLUSION: To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients' blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. PMID: 31104010 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
CONCLUSIONS: These results indicated that tiRNA-5034-GluTTC-2 may be a novel biomarker for the diagnosis of gastric cancer. PMID: 31104009 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Authors: Wu Z, Huang W, Chen Y, Chen B, Liu R, Bai P, Xing J Abstract LINC01638 lncRNA is known as an oncogenic lncRNA in triple negative breast cancer. However, the role of LINC01638 lncRNA in other diseases is unknown. In the present study we observed that plasma levels of LINC01638 lncRNA and Notch1 were upregulated in prostate carcinoma patients comparing with healthy controls. LINC01638 lncRNA and Notch1 were positively correlated in prostate carcinoma patients but not in healthy controls. Upregulation of LINC01638 lncRNA distinguished prostate carcinoma patients from healthy controls. LINC01638 lncRNA overexp...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
CONCLUSIONS: BCL2L12 protein expression could be used as a favorable prognostic tissue biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC. PMID: 31104007 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Immunosenescence is the name give to the age-related decline in effectiveness of the immune system. Some authors consider this to be distinct from inflammaging, the growth in chronic inflammation due to overactivation of the immune system in response to molecular damage and the presence of senescent cells, while others consider that chronic inflammation to be an aspect of immunosenescence. In today's open access paper, researchers review immunosenescence from the perspective of the adaptive immune system, here meaning detrimental changes in T cell populations. The contributing causes of these changes are given as (a) the a...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Publication date: Available online 20 May 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Ilari Kuitunen, Miia Artama, Antti Eskelinen, Eerik T. Skyttä, Heini Huhtala, Jukka UotilaAbstractObjectiveOnly a few small studies have been published on pregnancies after total hip replacement (THR), and they have reported no adverse pregnancy outcomes after THR. The aim of our study was to evaluate whether maternal THR affects pregnancy outcomes on a population-based level.Study DesignData for this nationwide register-based cohort study have been collected from four national regist...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
More News: Arthritis | Biology | Blogging | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Colorectal Cancer | Genetics | Humira | Internet | Leukemia | Lung Cancer | Melanoma | National Institute for Health and Clinical Excelle | Pancreas | Pancreatic Cancer | Pharmaceuticals | Psoriasis | Rheumatology | Science | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Websites